Expression of NRASQ61R-HA from nine different tumor samples (54, 286, 287, 360A, 360B, 332, 333, 335 and 336). The A and B designation indicates two separate tumors from the same mouse. Samples 54, 286, 287, and 360A and B were derived from tumors induced by injection of DCT-TVA/Ink4a/Arf lox/lox mice with viruses containing NRASQ61R and Cre while samples 332, 333, 335, and 336 were derived from subcutaneous injection of tumor cells into DCT-TVA/Ink4a/Arf lox/lox mice. The cells were lysed in SDS lysis buffer and separated on 4-20% gradient polyacrylamide gels. Virally delivered NRAS expression was detected with an antibody to the HA epitope tag on NRAS. NRAS activity was evaluated by blotting for phosphorylated ERK1/2 (p-ERK 1/2) and comparing the levels of total ERK 1/2 expression. Activity of Cre was evaluated by blotting for p19 Arf expression. D6-MEL immortal melanocytes were used as a negative control for HA expression and normal mouse astrocytes were used as a positive control for p19 Arf expression. The blots were re-probed with α-tubulin as a loading control.